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Board of Pharmacy
Executive Officer: Patricia Harris * (916) 445-5014 * Internet www.dca.ca.govlpharmacy/
ursuant to Business and Professions Code section 4000
mation is entered on the label of the
i
t
et seq., the Board of Pharmacy grants licenses and perprescription container; (3) a premits to pharmacists, pharmacy interns, pharmacy techscription is dispensed with the wrong drug or wrong drug
nicians, pharmacies, pharmacy corporations, nonresident
dosage; (4) a drug is dispensed that is contraindicated if taken
pharmacies, wholesale drug facilities, medical device retailwith another drug; or (5) a prescription is filled with a mediers, veterinary food-animal drug retailers, out-of-state discation whose expiration date has passed. Consistent problems
tributors, clinics, and hypodermic needle and syringe distribucontributing to prescription errors are the absence or prestors. It regulates all sales of dangerous drugs, controlled subence of computerized placeholders that are zeroes before and
stances, and poisons. The Board is authorized to adopt reguafter the decimal point in the dosage of a medication; misinlations, which are codified in Division 17, Title 16 of the
terpreted abbreviations and incomplete medications; poor
California Code of Regulations (CCR).
communication (including illegible prescriber handwriting
To enforce the Pharmacy Law and its regulations, the
[15:1 CRLR 87]); similarities in product names; ambiguities
Board employs full-time inspectors who investigate comin directions for use or medical abbreviations; unclear labelplaints received by the Board. Investigations may be coning; and poor pharmacy procedures or techniques. Some pharducted openly or covertly as the situation demands. The Board
macists complain that their workload-the number of preconducts fact-finding and disciplinary hearings, and is auscriptions to be filled with insufficient staffing-may also
thorized by law to suspend or revoke licenses or permits for a
cause prescription errors.
variety of reasons, including professional misconduct and any
Obviously, a medication error can result in patient injury
misconduct substantially related to the practice of pharmacy.
or death. To prevent such harm, the Board on July 30 pubThe Board of Pharmacy is a consumer protection agency
lished notice of its intent to adopt new section 1717.5, Title 16
located within the Department of Consumer Affairs (DCA).
of the CCR, which would require every licensed pharmacy to
The Board, which meets five
develop and implement a quality
times per year, consists of eleven Obviously, a medicatioPr
assurance program (QAP) to docuin
result
n error can
members, four of whom
are patient injury or death."
emaiing
ment medication errors attributable
harm,
nonlcenses.The
such
nonlicensees. The remaining
the Board on July 30 p o prevent
to a pharmacy or its personnel. The
its
of
notice
seciblished
toadon
te
members are pharmacists, five of
purpose of the QAP is not
primary
of
16
the CCR, which would t ion 1717.5,Title
whom must be active practitiorather, it is to document
punitive;
licensed
every
ners. All Board members are ap- pharmacy to develop an 2quire
medication errors in
analyze
and
quality
a
I implement
Id
aracy togramelo
pointed for four-year terms.
the pharmacy to
enable
to
order
medication
On May 21, Assemblyprogram
On 21
My Assmbly errors attributabletotcdocument
action to prevent
appropriate
take
its
or
a pharmacy
Speaker Antonio Villaraigosa ap- personnel.
a recurrence. For purposes of the
the
pointed Andrea Zinder as
required QAP, section 1717.5
Board's newest public member;
would define the term "medication
Zinder replaces Kenneth Tait. Zinder is currently an execuerror" as "any preventable event that may cause or lead to, or
tive assistant to the President of the United Food and Comthat has caused or led to, inappropriate medication use or pamercial Workers Union Local 324, where she has worked since
tient harm while the medication is in the possession of or un1984. While working at UFCW, she has represented retail
der the control of the pharmacy, another health care profesworkers and drugstore employees, including pharmacists, in
sional, or the patient or consumer. The circumstances or activicontract negotiations.
ties that may lead to or create a medication error include, but

MAJOR PROJECTS
Prevention of Medication Errors:
QualityAssurance Program Regulations
The Board's primary responsibility is to protect the public health, safety, and welfare of California's patients. The
Board has become increasingly concerned about the growing
incidence of medication errors [16:2 CRLR 55], which can
include any of the following: (1) the prescriber orders an inappropriate drug for a patient's condition; (2) incorrect infor-

are not limited to: receipt and use of health care products, including drugs and devices; receipt of prescriptions, including
communication, interpretation, and evaluation of an order; drug
selection, compounding and dispensing, including direction and
supervision of pharmacy personnel; provision to patients, including selection, preparation and labeling of the prescription
container, use of patient profiles, prescriber contacts, and patient consultation and education; patient use, including dispensing and use of refills and monitoring of patient use; general
pharmacy administration, procedures, and systems; professional
pharmacy practice."
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Section 1717.5 would require every pharmacy to describe
Emergency Regulations to Implement
its QAP in its policies and procedures manual, and would
SB 188 (Leslie): Pharmacy Operations
specify the required contents of the QAP. At minimum, the
During Temporary Absence of a Pharmacist
QAP analysis of medication errors must consider workplace
At its October 20 meeting, the Board considered the
conditions, including general working conditions, peak
adoption of new section 1714.1, Title 16 of the
emergency
workload periods, and workplace design and operation; the
CCR, to implement SB 188 (Leslie) (Chapter 900, Statutes
use of technology; and training and ongoing evaluation of
of 1999). SB 188 was amended late in the legislative year to
staff, including adequacy of training and evaluation to prorequire the Board to adopt regulations accommodating the
tect public health and safety. Section 1717.5 would require
temporary absence of a pharmacist from a pharmacy; SB 188
each pharmacy to document in its QAP, for each medication
and the new regulations became
error, the fact that a QAP was conducted; the findings and determi- Although many agreec with the concept of a necessary after the Governor
QAP as an internal edu c ational tool to analyze signed SB 651 (Burton), which
nations made by the pharmacy;
the circumstances ar reasons for errors, mandates breaks and lunch periand remedial efforts undertaken,
opponents argued that' e provision's definition ods for pharmacists during the
if any, including communication
of "medication error' piis far too broad and workday (see LEGISLATION).
to pharmacy personnel responexpressed concern abo ultthe discoverability of Absent new regulations, the comsible for the error and to pharmacy
bination of SB 651 and the existpersonnel in general. The phar- a pharmacy's QAP by aintiff attorneys.
ing Pharmacy Law will require the
macy must maintain records of all
of a pharmacy and the reclosure
activities undertaken as part of its
personnel
from the pharmacy
all
non-pharmacist
moval of
QAP for at least three years, and make those records accesarea during pharmacist breaks and lunch periods when SB
sible to the Board during normal business hours. The section
651 takes effect on January 1, 2000.
would also specify that compliance with the QAP requireAs drafted by the Board's Legislation and Regulation
ment may be considered by the Board as a mitigating factor
emergency section 1714.1 would state that in
Committee,
in an investigation and evaluation of any medication errors.
staffed
by a single pharmacist, the pharmacist may
pharmacies
On October 20, the Board held a public hearing on propharmacy
temporarily for breaks and meal periods
leave
the
and
represenNumerous
pharmacists
posed section 1717.5.
closing
the
pharmacy and removing ancillary staff
without
compatatives of pharmacies, retailers, and pharmaceutical
believes that the security of the
the
pharmacist
reasonably
"if
Although
the
QAP
requirement.
nies registered opposition to
be maintained in his or her
and
devices
will
dangerous
drugs
an
internal
educaof
a
QAP
as
with
the
concept
many agreed
absence." If not, the pharmacy
tional tool to analyze the circumarea (the area in which prescripstances and reasons for errors, opns
of
tion drugs and devices are kept)
the
combination
new
regulatio
the
Absent
argued
that
ponents
provision's definition of"medica- SB 651 and the existin g Pharmacy Law will must be closed and non-pharmation error" is far too broad and require the closure of a pharmacy and the cist employees must be removed
expressed concern about the removal of all non-pha rrnacist personnel from during the pharmacist's absence.
discoverability of a pharmacy's the pharmacy area duiring pharmacist breaks Section 1714.1 would also state
QAP by plaintiff attorneys. Sev- and lunch periods wh en SB 651 takes effect that during the pharmacist's absence, no prescription medication
eral witnesses stated that the on January 1, 2000.
may be provided to a patient or to
discoverability of a QAP in civil
a patient's agent unless the prelitigation would discourage the rescription medication is a refill that the pharmacist has checked,
porting of errors, and argued that a pharmacy's QAP should
released for furnishing to the patient, and was determined not
be immune from discovery in civil actions. Many opponents
to require the consultation of a pharmacist.
stated that the focus should be on preventing errors instead of
Under the draft regulation, ancillary staff (including pharreporting and investigating them after they occur; these opmacy
technicians and intern pharmacists) may continue to
ponents argued that errors that are caught by pharmacy pernondiscretionary duties authorized by law during the
perform
to
a
consumer
should
sonnel before medication is dispensed
temporary absence of a pharmacist, but the pharmacist must
not have to be reported in the QAP. The California Pharmareview any duty performed by ancillary staff upon his/her
cists Association (CPhA) also argued that the Board should
return to the pharmacy. The proposal also states that in pharon
pharmacies
reevaluate the fiscal impact of this proposal
macies
where two or more pharmacists are on duty, the pharsubject to the QAP requirement.
macists
must stagger their breaks and meal periods to ensure
20
hearAfter much debate and testimony at the October
the
pharmacy is not left without a pharmacist for a temthat
ing, the Board unanimously deferred adoption of section
porary period. Finally, section 1714.1 would require pharma1717.5's current language and remanded this matter to its
cies to draft written policies and procedures regarding the
Enforcement Committee for further study.
.,
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is not on probation with the Board. Further, the storage area
must be maintained so that records are secure and the confidentiality of any patient-related information is maintained;
the address of the site and the key to the storage area must
maintained on the licensed premises by an employee licensed
by the Board, and must be immediately accessible to the pharmacist-in-charge and upon request to the Board or other law
enforcement officer; and the records in storage must be retrievable within two hours and at all times open to inspection
during business hours upon the request of the Board or other
law enforcement officer. Under the proposal, in the event that
a licensee fails to comply with the above provisions, the Board
may cancel the waiver without a hearing, at which time the
licensee must maintain all records at the licensed premises.
The proposal also specifies the method of reapplying for a
waiver in the event one has been canceled by the Board.
In its May 21 notice, the Board did not schedule a public
Waiver Requirements for Offsite
hearing on proposed section 1707, but several licensees reStorage of Drug Records
quested a hearing under Government Code section 11346.8(a).
On June 22, the Board issued a notice stating that it would
Business and Professions Code section 4081 requires
hold a public hearing on section 1707 at its July 28 meeting
Board licensees to make available for Board inspection durin Burlingame. On July 7, the Board released a modified vering business hours all records of the manufacture, sale, acsion of section 1707, in which it added a new subsection to
quisition, or disposition of prescription drugs or devices.
the provision. The new language states that "notwithstanding
Additionally, section 4105 requires "all records or other docuthe requirements of this section, any entity licensed by the
mentation of the acquisition and disposition of dangerous
Board may store the records described in subdivisions (a),
drugs and dangerous devices by any entity licensed by the
(b), and (c) of section 4105 of the Business and Professions
Board... [to] be retained on the licensed premises in a readily
Code in a storage area at the same address or adjoining the
retrievable form," and section 4333 requires pharmacies to keep
licensed premises without obtaining a waiver from the Board
records of all prescriptions filled on pharmacy premises and
if the following conditions are met: (1) the records are readily
available for inspection by Board personnel and other authoaccessible to the pharmacist-in-charge (or other pharmacist
rized law enforcement officers for at least three years. Howon duty, or exemptee) and upon request to the Board or any
the
Board
authorize
ever, subsections 4105(e) and 4333(c)(1)
authorized officer of the law; and (2) the storage is mainwritten
request.
upon
storage
requirement
to waive the onsite
tained so that the records are secure and so that the confidennumincreasing
received
an
the
Board
has
years,
In recent
tiality of any patient-related information is maintained."
requirestorage
of
the
onsite
ber of applications for waiver
At the July 28 hearing, the
any
of
not
granted
but
has
ment,
Retailers' Association
California
realizes
them. However, the Board
at it is not always feasible and Longs Drugs objected to the
th
realizes
Board
The
or
feasible
always
not
is
it
that
or practical for a bu sin ess to maintain all of two-hour requirement for records
practical for a business to mainits records on the lice nseed premises,and seeks retrieval, arguing that the Board
tain all of its records on the lins codifying standard should consider a more reasoncensed premises, and seeks to to adopt regulatio
o uld determine which
able time limit in light of potenadopt regulations codifying stan- criteria by which it
be
tial traffic and other delays; Longs
a
waiver,
and
granted
license holders might
dard criteria by which it would dele
stated that the U.S. Drug Enforcedisciplinary
to
pursue
ensuring that it is ab
termine which license holders
ment Administration (DEA) reits
duties
ee
violate
might be granted a waiver, and en- action should a licens
quires offsite records to be retrievge.
ira
suring that it is able to pursue dis- regarding records sto
able within 72 hours. CPhA obciplinary action should a licensee
jected to the regulations as unnecessary and expensive for
violate its duties regarding records storage.
pharmacies; the trade association asserted that the legislative
Thus, on May 21, the Board published notice of its inhistory of the statutory waiver provisions was intended to
Under
the
CCR.
tent to adopt new section 1707, Title 16 of
permit routine waivers of the onsite storage requirement, not
the proposed section, a waiver authorizing offsite storage of
to require pharmacies to qualify for a waiver. CPhA called
drug records may be granted to a Board licensee if the licfor
fairly automatic waivers upon request, and substantial simensee has no history of failure to produce records upon the
of the regulatory language. Kaiser Permanente also
plification
request of the Board or other law enforcement officer, no histo
the Board's proposal, noting that many hospitals
objected
tory of violations related to recordkeeping, and the licensee

operation of the pharmacy during the temporary absence of
the pharmacist for breaks and meal periods.
Following its receipt of a number of comments from
pharmacist and labor organizations, the Board modified the
language of section 1714.1 to add a provision stating that "a
pharmacist who takes a break in compliance with this section
shall not be subject to California State Board of Pharmacy
disciplinary action or citation for acts that he or she did not
authorize and that he or she, by the exercise of reasonable
care, could not have prevented during his or her absence."
The Board adopted section 1714.1 as modified, and instructed
staff to forward the proposed emergency regulation to DCA
and the Office of Administrative Law (OAL) for approval.
At this writing, staff is preparing the rulemaking file on section 1714.1; if approved by OAL, the emergency regulation
will be effective on January 1, 2000 for 120 days.
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do not have sufficient physical space for records storage.
subject to citation and fine to include noncompliance with the
Board's continuing education requirement, add violation of the
Kaiser's records are stored in two centers where a pharmacist
Board's regulations as a justification for the issuance of a citais not in charge; rather, the records are maintained by a "protion and/or fine, and update the statutory references in the secfessional storage manager." Following the hearing, the Board
tions to reflect the 1996 reorganization of the Pharmacy Law.
decided to substantially modify the language of section 1707
The Board did not hold a public hearing on these proand to republish the section with its modifications.
posed
amendments, but accepted written comments until July
of
a
revised
version
Board
published
On August 20, the
5.
At
its
July 28 meeting, the Board considered several comsection 1707, Title 16 of the CCR. Under the August 20 lanments
that
it had received, and adopted the regulatory changes
guage, the Board "shall" grant a waiver of the onsite storage
subject
to
several minor revisions. The Board directed staff
requirement to any licensee for offsite storage of the records
to
release
the
revised version of sections 1775 and 1775.1 for
described in Business and Professions Code subsections
prean
additional
15-day comment period, and then submit the
4105(a), (b), and (c), unless the applicant has, within the
rulemaking
file
on the proposed changes to DCA and OAL
ceding five years, failed to produce records pursuant to secfor
approval.
tion 4081 or has falsified records covered by section 4081.
In a related matter, at its October 20 meeting the Board
However, even under this waiver, all prescription records must
discussed
staff's proposal to substantially expand its rather
be maintained on the licensed premises for a period of two
narrow citation and fine regulations to permit the issuance of
years from the date of dispensing. Any licensee granted a
citations and/or fines for violations such as abandonment of
waiver must maintain the offsite storage area so that the
a pharmacy, failure to produce records when requested by
records are secure, including from unauthorized access, and
the Board, absence of a pharmamust be able to produce the
records within 48 hours upon the Deputy Attorney Ge ne ral Bill Marcus noted cist from a pharmacy, failure to
request of the Board or other authat other occupatiol
ial licensing boards have notify the Board of a change of
thorized law enforcement officer. used the citation and fin e remedy expansively address, license lapse of pharThe proposed regulation states for minor offenses,an d t he result isfewer cases macy technicians, and other relathat if a licensee fails to comply being referred to theAbtt orney General's Office tively minor violations. Deputy
with these conditions, its waiver for full-blown adju
Attorney General Bill Marcus
dic ation (and reduced
noted that other occupational liwill be canceled without a hear- enforcement costs fo
censing boards have used the cirs
ing (such that all records must be
tation and fine remedy expanmaintained at the licensed premises), and provides a method of reapplying for another
sively for minor offenses, and the result is fewer cases being
waiver. Proposed section 1707 also expressly permits licensreferred to the Attorney General's Office for full-blown adjuees to store the records described in subdivisions (a), (b), and
dication (and reduced enforcement costs for such boards).
Following discussion, the Board approved staff's proposal;
(c) of section 4105 of the Business and Professions Code in a
storage area at the same address or adjoining the licensed
at this writing, staff is drafting more expansive citation and
fine regulations for public notice and comment in the future.
premises without obtaining a waiver from the Board if the
records are readily accessible to the pharmacist-in-charge (or
Dangerous Drugs and Devices Exempt
other pharmacist on duty, or exemptee) and upon request to
From Storage in a Pharmacy
the Board or any authorized officer of the law, and the storSB 1308 (Committee on Business and Professions)
age is maintained so that the records are secure and so that
the confidentiality of any patient-related information is main(Chapter 655, Statutes of 1999) amended Business and Professions Code section 4057 to remove from statute two lists
tained.
of dangerous drugs and devices that are exempt from the PharThe Board did not schedule another public hearing on
macy Law's requirements and may be stored outside a
the revised language of section 1707, but accepted written
comments until October 4. At its October 20 meeting, the
pharmacy's licensed premises when furnished to specified
licensed individuals or entities. Instead, SB 1308 directs the
Board discussed a comment received from Kaiser Permanente
Board to list these exempt drugs and devices in regulation.
calling for additional modifications to the language. The Board
Thus, on October 29, the Board published notice of its
took no action on section 1707 at its October meeting, and is
intent to adopt section 1714.5, Title 16 of the CCR, to place
expected to revisit the proposal at its January 2000 meeting.
in regulation two lists of dangerous drugs and devices that
Citation and Fine Regulations
are exempt from required storage in a pharmacy, provided
On May 21, the Board published notice of its intent to
they are obtained by a person or entity meeting specified liamend section 1775 and 1775.1, Title 16 of the CCR, which
censure and practice criteria. Specifically, the section would
implement the Board's citation and fine authority under Busiset forth a list of drugs and devices which need not be stored
ness and Professions Code sections 125.9 and 148. The purin a licensed pharmacy so long as they have been sold or
poses of the amendments are to expand the listing of violations
furnished to a physician, dentist, podiatrist, pharmacist, mediCalifornia Regulator), Law Reporter* Volume 17, No. I (Winter 2000)
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subject to several minor modifications. Specifically, the Board
amended the section to require the prescription container to
be clearly labeled with all information required by Business
and Professions Code section 4076, plus the name and address of the pharmacy refilling the prescription and/or the
name and address of the pharmacy that receives the refilled
prescription for dispensing to the patient.
On June 3, Board staff released the modified version of
section 1707.4 for an additional 15-day comment period ending June 21. At this writing, DCA is considering the
rulemaking file on section 1707.4; after DCA approves the
file, it will be forwarded to OAL for approval.
* Medical Device Retailer Location Restrictions. On
May 20, the Board adopted new section 1748.3, Title 16 of
Update on Other Board Rulemaking
the CCR, which explicitly prohibits a medical device retailer
from conducting business from a private residence and from
The following is an update on recent Board rulemaking
locating a warehouse, the primary purpose of which is storproceedings described in detail in Volume 16, No. 2 (Sumage of medical devices, at a private residence. Under Busimer 1999) of the CaliforniaRegulatory Law Reporter:
ness and Professions Code section 4132(0, medical device
* Refill Pharmacy Regulations. Recently, many new
retailers are required to make their records of sale, purchase,
pharmacy operations and concepts have begun to emerge. One
and disposition of dangerous devices available, at all times
such concept is a refill pharmacy, which prepares refill preduring business hours, for inspection by authorized law enscriptions for another pharmacy. While the Board has licensed
forcement officers. When persons conduct a medical device
such pharmacies in the past, it has determined that labeling
retail business from their home or the home of someone else,
and documentation requirements should be established to
Pharmacy Board inspectors and authorized law enforcement
assure that patients can readily determine where the prescripofficers have encountered problems gaining access to records
tion was filled. Thus, in February 1999, the Board published
because of residential privacy issues. The new regulatory secnotice of its intent to adopt section 1707.4, Title 16 of the
tion eliminates this problem. [16:2 CRLR 50] At this writing,
CCR, to address its concerns about the use of refill pharmaDCA is considering the rulemaking file on section 1748.3;
cies. The purpose of the Board's proposal is to (1)allow a
after DCA approves the file, it will be forwarded to OAL for
pharmacy to utilize the services of another pharmacy to proapproval.
vide refills if it has a contract for these services or has com* FurnishingofDrugs andDevices by Wholesalers and
mon ownership; (2) specify the labeling requirements for a
Manufacturers. On May 20, the Board adopted new section
prescription refilled at a refill pharmacy, including the name
1783, Title 16 of the CCR, to clarify the identity of"authoof the refill pharmacy and which pharmacy the patient should
rized
persons" to whom drug manufacturers and wholesalers
contact if he/she has questions (this information may be either on the label or in writing acmay furnish dangerous drugs and
companying the medication); (3) On May 20, the Boa
devices under Business and Prot ne section fessions Code section 4163. [16:2
rd ,ta
specify the documentation requireI783,Title 16 of the C
nto clarifythe identity CRLR 50-51] Under section
ments for the originating pharmacy of "authorized per CR
rso ons" to whom drug
1783, the term "'authorized perand the refill pharmacy; and (4) manufacturers and
eviesuder ma urins
son" means a person to whom the
allow a pharmacy to operate as a
de i nder Busines Board has issued a permit which
refill pharmacy as well as fill new and Professions Cod( S*
enables the permit holder to purprescriptions. [16:2 CRLR 50]
chase dangerous drugs or devices
On May 19, the Board held a
for
use
within
the
scope
of
its permit. "Authorized person"
public hearing on its proposed adoption of section 1707.4.
also
means
any
person
in
California
or in another jurisdiction
Most witnesses favored the proposal, although Steve Gray
within
the
United
States
to
the
extent
such furnishing is aufrom Kaiser Permanente clarified that three pharmacies may
thorized
by
the
law
of
this
state,
any
applicable
federal law,
be involved in a refill transaction-the pharmacy that receives
and
the
law
of
the
jurisdiction
in
which
that
person
is located.
the refill request, the pharmacy that refills the prescription,
The
manufacturer
or
wholesaler
furnishing
to
such
a person
and the pharmacy that gives the refilled prescription to the
shall, prior to furnishing the dangerous drugs and devices,
patient. He recommended that the language of section 1707.4
establish that the intended recipient is legally authorized to
be modified to require that only the name and address of the
receive the dangerous drugs or devices. The section is inpharmacy that refills the prescription appear on the prescriptended to eliminate any confusion on the part of drug wholetion container label. Following public comment mostly in
salers and manufacturers regarding with whom they may make
support of the proposal, the Board adopted the section
cal technician, medical technologist, optometrist, or chiropractor holding a currently valid and unrevoked license and
acting within the scope of his/her practice, or to a clinic, hospital, institution, or establishment holding a currently valid
and unrevoked license or permit under specified sections of
the Health and Safety Code or the Welfare and Institutions
Code. Proposed section 1714.5 would also set forth a separate list of drugs and devices which need not be stored in a
licensed pharmacy when a licensed home health agency or
hospice purchases, stores, furnishes, or transports them.
At this writing, the Board does not intend to hold a public hearing on section 1714.5; however, it is accepting written comments until December 13.
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arrangements for the purchase and delivery of drugs, and to
ensure that these drugs are maintained at all times by licensees or their designated agents. OAL approved the new section on August 25.

Pharmacy Practice on the Internet
At its October 20 meeting, the Board discussed draft legislation to address the recent and potentially dangerous proliferation of pharmacy practice activity on the Internet. Although the Pharmacy Law requires an Internet pharmacy
which offers to compound, dispense, or refill a prescription
for a resident of California to be

of approval. Further, Marcus' draft statutory language would
provide the Board with the ability to impose civil penalties
against Internet pharmacies that do not comply with this
legislation.
The Board acknowledges that many consumers prefer to
purchase prescription drugs over the Internet because of the
convenience, access, and occasional cost savings. Some
Internet pharmacy sites are safe, secure, and run by responsible pharmacists who abide by the Board's laws and regulations, and the Board realizes that it must proceed cautiously
so as not to impede lawful commerce by these entrepreneurs.
However, other pharmacy sites

licensed by the Board as a non- Although the Phar
are seeking only to make a quick
maacy Law requires an
resident pharmacy (such that the
Internet pharmacy w h offers to compound, profit, and can easily shut down
hic
Board has disciplinary jurisdic- dispense, or refill a pr
'es cription for a resident (and reopen almost instantly untion over it), enforcement of that of California to be lic
en sed by the Board as a der another address) if any govrequirement in the Internet envinonresident pharma cy
(such that the Board ernment agency seeks to investironment is difficult. Although the
has disciplinary j
ur isdiction over it), gate them. The VIPPS program
Board's Licensing Committee has enforcement of th2
t requirement in the may enable consumers to tell the
requested that the Board sponsor
Internet environmen t is
difference; however, consumers
difficult,
legislation to regulate Internet
must be educated to expect and
demand such information. Thus,
pharmacy practice and Deputy
Attorney General Bill Marcus has attempted a draft, the
the industry and the Board must educate consumers about
how to safely use the Internet to purchase drugs. Following
Committee's study thus far has resulted in conclusions similar to those reached by the Medical Board's Committee on
discussion, the Board agreed that its Licensing Committee
Internet Prescribing: Internet practice is a global problem,
and its Legislation and Regulation Committee should take
far bigger than any state licensing board or even federal agency
another look at the proposed legislation, circulate it to intercan address. Perhaps the most any state agency can do is eduested parties, and incorporate appropriate changes before any
cate consumers to exercise extreme caution when purchasing
decision is reached on its introduction.
dangerous drugs or devices over the Internet (see agency reImplementation of the FDA
port on MEDICAL BOARD OF CALIFORNIA for related
Modernization Act of 1997
discussion).
The legislation drafted by Marcus and considered by the
The FDA Modernization Act of 1997, which became efBoard in October would establish the following requirements
fective in November 1998, requires the U.S. Food & Drug
for an out-of-state Internet pharmacy dispensing prescription
Administration (FDA) and the fifty states to enter into a
drugs to California residents: (1) it must be licensed by the
memorandum of understanding (MOU) regarding the comBoard as a nonresident pharmacy,
pounding of drugs. Compounding
and must be licensed as a pharis the process by which a pharmacist combines, mixes, or alters
macy in its home state; (2) it may Some Internet pharn ac y sites are safe,secure,
ep
harmacists
who
abide
ingredients to specialize a mediresponsibl
by
run
and
by
not be foreign-based or owned
inc
i
regulations,
and
the
cation
for a patient, at the direclaws
Board's
the
by
offer
prescribers; (3) it may not
Ist
proceed
cautiously
tion
of
a
physician. Section 503A
it
that
realizes
Board
the
prescribing-based sites where
rul
commerce
by
I
.wf
these
of
the
Act
recognizes compoundimpede
to
not
as
so
to
prescriber issues a prescription
entrepreneurs.
online
a consumer based upon an
ing as an element of the practice
questionnaire; (4) it may only acof pharmacy that is to be regucept a faxed prescription from a prescriber (it may also related by the states, and distinguishes it from "manufacturceive a faxed prescription from a patient, but must receive
ing" which falls within the jurisdiction of the FDA. The purthe original prescription from the patient prior to filling the
pose of the section is to ensure continued availability of comprescription); (5) it must disclose on its homepage its name,
pounded drug products as a component of individualized
location, toll-free number, and California license number; and
therapy, while limiting the scope of compounding so as to
(6) it must be registered with the Verified Internet Pharmacy
prevent manufacturing under the guise of compounding." The
Practice Site (VIPPS) program administered by the National
purpose of the MOU is to address the interstate distribution
Association of Boards of Pharmacy. NABP has developed
of "inordinate amounts" of compounded drug products and
the VIPPS program to certify Internet pharmacy sites if they
the related issue of state investigations of complaints regardmeet certain criteria, similar to a "Good Housekeeping" seal
ing this distribution.
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The law instructs the FDA to promulgate regulations
macies, largely small specialist pharmacies, complained that
both the 5% "safe harbor" and the 20% "inordinate" limits
establishing the parameters of the MOU, and to consult with
the National Association of Boards of Pharmacy (NABP) to
are arbitrary, and that the 20% limit will not allow their phardevelop a standard MOU for state boards. The goal of the
macies to remain financially viable or serve patients who
MOU is to obtain state agreement on two issues: (1) protobenefit from their specialized practices. These compoundcols for the appropriate investigation of complaints relating
ing pharmacies also noted that the MOU has no effect on
to compounded drug products shipped out-of-state; and (2)
chain pharmacies with outlets in multiple states; the compounding pharmacies contended that, because of their many
establishment of appropriate restrictions on the amount of
compounded drugs shipped in interstate commerce, includlocations and large volume of prescriptions orders, interstate chain pharmacies are being granted a monopoly on
ing "safe harbors" for pharmacists who distribute compounded products in interstate commerce. Pharmacies locompounded drugs.
cated in a state that did not sign an MOU by the law's effecFollowing public comment and discussion, the Board detive date (November 21, 1998) are subject to FDA's "safe
cided to write a letter to FDA objecting to both the 20% annual limitation on compounded
harbor" provision, whereby comdrugs distributed interstate and the
pounded products may not ex50-mile geographic restriction.
The Board stressed th at the MOU should focus
ceed 5% of the total prescription
nig
pharmacy
does
and
The Board stressed that the MOU
dir
on what the compour
orders dispensed or distributed by
w
much
it
does;
in
other
should focus on what the comho'
how it does it, not
that pharmacy. [16:2 CRLR 51;
ns
should
focus
on
the
pounding
pharmacy does and how
words, the regulatio
16:1 CRLR 71-72]
rm
iaceutical
products
it
does
it,
not how much it does;
pha
quality of the
In January 1999, FDA pubq,
uantity.
in
other
words,
the regulations
thi
not
compounded,
lished draft regulations and a
draft MOU which have been
greeted by opposition from compounders and state boards
alike. Among other things, the draft MOU requires the Board
to agree to take action against a pharmacy that engages in
the interstate distribution of compounded drugs under either of the following circumstances: (1) the number of compounded prescriptions dispensed or distributed interstate
annually by the pharmacy is equal to or greater than 20% of
the total number of prescriptions dispensed or distributed
(including both intrastate and interstate) by that pharmacy;
or (2) the number of compounded prescriptions dispensed
or distributed interstate annually by a pharmacy is less than
20% of the total number of prescriptions dispensed or distributed (including both intrastate and interstate) by that
pharmacy, but prescriptions for one or more individual compounded drug products (including various strengths of the
same active ingredient) dispensed or distributed interstate
constitute more than 5% of the total number of prescriptions dispensed or distributed. Compounded drugs that are
distributed interstate but "locally" are excluded from the
calculation to determine the number of compounded prescriptions dispensed or distributed annually by a pharmacy,
but the MOU defines the term "locally" to mean distribution by a pharmacy to patients located within 50 miles of
the pharmacy (notwithstanding that such patients live in
another state)-thus requiring compounding pharmacies to
keep close track of the mileage between their address and
the address of their patients. Apparently, pharmacies that
exceed the 20% limit must be licensed by FDA as manufacturers.
At its July 28 meeting, the Board heard extensive public comment from compounding pharmacies and reviewed
other written comments that national compounding associations have submitted to FDA. The compounding phar-

should focus on the quality of the
pharmaceutical products compounded, not the quantity. At
this writing, the FDA has neither adopted final implementing
regulations nor released a final MOU; once FDA releases the
MOU, the Board must decide whether to sign it.

LEGISLATION
SB 1308 (Committee on Business and Professions), as
amended September 2, enacts various technical changes affecting licensing boards within DCA. Several of the bill's
provisions amend the Pharmacy Act in the Business and Professions Code, including the following:
- The bill amends section 4022 to revise the definition
of "dangerous drug or device" to include drugs or devices
bearing the statement "Rx only." This change conforms
California's definition of "dangerous drug or device" to the
federal definition.
- SB 1308 amends section 4043 and adds section 4040.5
to the Code to clarify that "reverse distributors" (companies
that remove outdated/non-saleable drug products from pharmacies for disposal) and brokers (those who arrange for the
sale of drugs but may not take actual possession of the drugs)
must be licensed as drug wholesalers by the Board.
- The bill amends section 4057 to permit the Board to
control through regulations (rather than statute) two lists of
dangerous drugs and devices that may be stored outside a
pharmacy's licensed premises when dispensed or furnished
to specific licensed individuals or entities. The Board is already engaged in rulemaking to adopt regulations containing
these lists (see MAJOR PROJECTS).
- SB 1308 amends section 4078 to permit a pharmacist
to place a false label on a prescription if the labeling is a
necessary part of a clinical or investigational drug program
approved by the FDA or a legitimate investigational drug
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dance with written policies, procedures, or protocols of that
project involving a drug previously approved by the FDA.
facility, home health agency, licensed clinic, or health care
The bill also permits false labeling in situations where, in the
service plan. As amended July 7, AB 261 additionally authomedical judgment of the prescriber, the labeling is necessary
rizes a pharmacist to perform those procedures or functions
for the proper treatment of the patient.
in any setting in accordance with the policies, procedures, or
pharmathat
a
to
specify
4102
- The bill amends section
protocols of a physician. The bill also revises the standards
cist may perform skin puncture in the course of routine pafor those policies, procedures, and protocols to require that,
tient assessment procedures.
the
period
at
a minimum, they require that the medical records of the
to
extend
0 SB 1308 amends section 4115.5
patient
be available to both the patient's prescriber and the
of time allowed for practical experience in a pharmacy from
pharmacist,
and that the procedures to be performed by the
six months to one year for pharmacy technician trainees enpharmacist relate to a condition for which the patient has first
rolled in training programs run by private or public schools.
* The bill amends section 4200.5 to clarify that those
been seen by a physician.
AB 261 was sponsored by CPhA and supported by the
seeking a retired pharmacist's license need not surrender their
Board.
The California Medical Association originally opposed
original wall certificate to the Board in order to retire their
the
bill,
but CPhA worked with CMA to amend the bill to
license.
resolve its concerns. Governor Davis signed AB 261 on Sep* SB 1308 also amends section 4202 to require an applicant for registration as a pharmacy technician to be a high
tember 15 (Chapter 375, Statutes of 1999).
SB 651 (Burton), as amended June 22, provides that a
school graduate or to possess a general education developperson employed in the practice of pharmacy is not exempt
ment equivalent.
from the coverage of the orders of the Industrial Welfare Com- The bill amends section 4402 to provide that the Board
mission unless he/she individually meets the criteria estabmay cancel any license that is not renewed within 60 days
after its expiration.
lished for exemption as an executive or administrative employee. The bill further provides that no person employed in
, Finally, SB 1308 amends section 11165 of the Health
the practice of pharmacy may be subject to any exemption
and Safety Code to expand the Controlled Substance Utilizafrom the coverage of the orders of the Industrial Welfare Comtion Review and Evaluation System (CURES) program to
include statistical analysis, education, and research, and exmission established for professional employees.
tend CURES until July 1, 2003. CURES was created in 1997
Prior to this bill, pharmacists were considered "profesas a three-year pilot project to electronically monitor the presional" employees and were exempt from IWC orders requiring mandatory breaks and lunch periods for employees. The
scribing and dispensing of Schedule II controlled substances
proponents of SB 651 argued that
by all practitioners authorized to
the exemption imposed signifiprescribe or dispense them.
CURES will eventually replace Under SB 651, pharm acists are no longer cant hardship on pharmacists,
exempt as "professional' emncp
ios n us
who routinely work twelve-hour
the paper-intensive "triplicate"
be
afforded
breaks
and
ln
per"adiodstrunves
days and are frequently denied
system currently used to track the
they
are
specifically
exenm
pt
as
"administrative"
breaks or lunch periods, simply
prescription and dispensing of
or
"executive"
staff.
Schedule II narcotics. While still
because they are licensed by the
in the pilot project phase, CURES
State of California. Under SB 651,
pharmacists are no longer exempt as "professional" employis being administered concurrently with the existing tripliees, and must be afforded breaks and lunch periods unless
cate system, to examine the comparative efficiencies between
the two systems. [16:2 CRLR 48-49; 16:1 CRLR 69-70] SB
they are specifically exempt as "administrative" or "'execu1308 also requires the Department of Justice, in consultation
tive" staff.
with the Board, to submit reports to the legislature on the
Without additional changes to existing law, the passage
effectiveness of the CURES program on January 1, 2000,
of SB 651 would have required the physical closing of pharmacies (at least the area in which prescription medications
2001, and 2002.
are kept), as well as the removal of all non-pharmacist staff,
SB 1308 was signed by the Governor on October 6 (Chapduring these temporary absences of a licensed pharmacist.
ter 655, Statutes of 1999).
Thus, the enactment of SB 651 prompted amendments to SB
AB 261 (Lempert). Existing law authorizes a pharmacist to perform certain patient management functions (e.g.,
188 (Leslie), which now requires the Board to adopt regulations governing the functioning of a pharmacy and the work
ordering or performing routine patient assessment procedures
of pharmacy technicians while a pharmacist is temporarily
such as temperature, pulse, and respiration; ordering drug
therapy-related laboratory tests; administering drugs and
absent from the licensed premises (see below). Governor
biologicals by injection; and adjusting the drug regimen of a
Davis signed SB 651 on July 26 (Chapter 190, Statutes of
patient) as part of the care provided by a health care facility,
1999).
a licensed home health agency, a licensed clinic, or a proSB 188 (Leslie). Existing law authorizes a pharmacy techvider under contract with a health care service plan, in accornician to perform nondiscretionary tasks only while assisting
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and while under the direct, immediate, and personal supervision and control of a pharmacist. Any pharmacist responsible for a pharmacy technician must be on the premises at
all times and the pharmacy technician must be within the
pharmacist's view, except when the pharmacy technician is
employed to assist in the filling of prescriptions for an inpatient of a hospital or for an inmate of a correctional facility.
As amended September 7, SB 188 requires the Board-notwithstanding the above limitations-to adopt regulations to
accommodate the temporary absence of a pharmacist for
breaks and lunch periods pursuant to Labor Code section
512 and the orders of the Industrial Welfare Commission
without closing the pharmacy. This change was prompted
by SB 651 (Burton), which mandates breaks and lunch periods for most pharmacists (see above). During temporary
pharmacist absence, a pharmacy technician may remain in
the pharmacy but may only perform nondiscretionary tasks;
the pharmacist remains responsible for the pharmacy technician and must review any task performed during the
pharmacist's temporary absence. The Board recently adopted
emergency regulations to implement this provision of SB
188 (see MAJOR PROJECTS).
Existing law generally prohibits any person from selling or dispensing any dangerous drug, or dispensing any
prescription, unless he/she is a licensed pharmacist. However, a licensed hospital that contains 100 beds or fewer
and does not employ a full-time pharmacist may purchase
drugs at wholesale for administration, under the direction
of a physician, to patients registered in the hospital or to
emergency cases under treatment in the hospital. These hospital drug dispensing activities operate under a so-called
"limited drug room license." SB 188 authorizes hospitals
that have a limited drug room license and that meet the statutory definition of a "small and rural hospital" to dispense
drugs to outpatients under limited circumstances, and
defines those circumstances. The bill is designed to assure
patients in rural areas that their needs for medication can be
met in a reasonable manner. SB 188, an urgency bill, was
signed by the Governor on October 9 (Chapter 900, Statutes of 1999) and took effect on that date.
AB 724 (Dutra), as amended September 7, is the "Year
2000 Problem Good Government Omnibus Act of 1999," and
is intended to address problems that may arise from Y2K computer failures. Among other things, AB 724 provides that,
notwithstanding any other provision of law, during the period commencing December 1, 1999, and ending February 1,
2000, a pharmacist may refill any refillable prescription subject to the number and terms of authorized refills, upon request of the person on whose behalf the prescription was written, provided (1) the prescriber is unavailable to authorize
the early dispensing of the medication refill, and (2) the refill
medication dispensed does not exceed the dosage prescribed
to sustain the patient with uninterrupted therapy during this
period. The Governor signed AB 724 on October 7 (Chapter
784, Statutes of 1999).

REGULATORY AGENCIES
SB 816 (Escutia). Existing law permits a nurse practitioner (NP) to "furnish" prescription drugs and devices, in
accordance with standardized procedures developed by the
NP and his/her supervising physician, under specified circumstances; the term "furnish" is defined as the ordering of a
drug or device in accordance with the standardized procedure, and transmitting an order of a supervising physician.
Existing law also permits a physician assistant (PA), under
specified circumstances and while under the supervision of a
physician, to administer or provide prescription drugs to a
patient, or transmit orally or in writing on a patient's record
or transmittal order, a prescription to a person who may lawfully furnish the medication. SB 816 adds "ordering" prescription drugs and devices to existing provisions of law permitting NPs and PAs to "furnish" or "transmit" drugs and
devices in accordance with procedures developed by the NP
or PA and his/her supervising physician. SB 816 also requires
all NPs and PAs who are authorized to furnish or issue drug
orders for controlled substances to register with the DEA.
This bill also defines the term "drug order" as an order
for medication which is dispensed to or for a patient, issued
by a NP or PA as an individual practitioner, within the meaning of the Code of Federal Regulations; and specifies that a
drug order issued by a NP or PA shall be treated in the same
manner as a prescription of the supervising physician. Finally,
the bill provides that all references to the term "prescription"
in the Business and Professions Code and the Health and
Safety Code shall include drug orders issued by NPs or PAs,
and deems the signature of a NP or PA on a drug order to be
the signature of a prescriber for purposes of the Business and
Professions Code and the Health and Safety Code (thus authorizing pharmacists to fill them). This bill was signed by
the Governor on October 7 (Chapter 749, Statutes of 1999).
AB 1545 (Correa), as amended September 3, expands
and clarifies existing law that permits NPs and PAs to furnish
prescriptions for medicine that are within standardized procedures, as long as certain conditions are met. Specifically,
AB 1545 permits a NP who is functioning pursuant to a standardized procedure or protocol, or a PA functioning under
the supervision of a physician, to hand to a patient of the
supervising physician a prescription drug prepackaged by a
physician, a manufacturer, or a pharmacist; and requires, if
applicable, that the name of the NP or PA appear on the container label of any such prescription. The bill also permits a
NP or PA to sign for the delivery of a complimentary sample
of a dangerous drug or device, and adds the Board of Registered Nursing and the Physician Assistant Committee to the
list of regulatory bodies to which the Board of Pharmacy is
required to forward all complaints related to the dispensing
of dangerous drugs or devices. This bill was signed by the
Governor on October 9 (Chapter 914, Statutes of 1999).
SB 838 (Figueroa), as amended April 28, allows the
Board to register a nonresident pharmacy that is organized as
a limited liability company (LLC) in the state in which it is
licensed. Merck-Medco Managed Care sponsored this bill to
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clarify that the Board may continue its longstanding practice
of registering nonresident pharmacies that are organized as
LLCs in their home states. An LLC-a hybrid between a partnership and a corporation-is a relatively new form of business organization in California. The Board registered out-ofstate LLC pharmacies at least through 1997. At that time,
DCA analyzed some uncodified language in the LLC law
which prohibits the organization of an LLC for the rendering
of professional services. Based on DCA advice, the Board
began to reject licensure applications from out-of-state LLC
pharmacies. [16:1 CRLR 70-71] The sponsor and its supporters maintain that this bill clarifies ambiguity created by
issuance of various legal opinions on the topic, and that certainty in the law is necessary in order to continue to provide
low-cost mail order medications. Governor Davis signed SB
838 on July 6 (Chapter 73, Statutes of 1999).
AB 1430 (Bates), as amended September 9, would have
made a number of changes relating to the prescription and receipt of drugs by Board licensees. First, it would have eliminated an existing prohibition and provided that dangerous drugs
or devices may be furnished without a prescription to a professional corporation, partnership, or other entity comprised of
licensed health care professionals who are lawfully able to receive these drugs, provided that specified criteria and procedures are met. Further, the bill would have eliminated an existing requirement that electronic data transmission prescriptions,
as defined, be reduced to writing by the pharmacist.
The Board worked with the bill's author and sponsor,
Kaiser Permanente, to resolve many concerns about AB 1430,
and all of the Board's requested changes were amended into
the bill. However, an eleventh-hour amendment to the bill
would have restricted the Board's authority to regulate drug
wholesalers by precluding it from enforcing new section 1783,
Title 16 of the CCR, for at least one year (see MAJOR
PROJECTS); thus, the Board opposed the bill. The Attorney
General's Office also opposed AB 1430, arguing that it would
(1) inappropriately broaden the authority of manufacturers
and wholesalers to provide dangerous drugs and devices, (2)
diminish the authority of the Board of Pharmacy to closely
monitor the acquisition and maintenance of such drugs by
providers, and (3) fail to provide strict policies and procedures for identification of those authorized to obtain dangerous drugs. On October 10, Governor Davis agreed with the
Board and the AG and vetoed AB 1430, expressing concern
that "this bill could create avenues for the illicit diversion of
controlled substances" and urging the author to work with
the Attorney General on crafting a product that eliminates
this potential. Because the Governor vetoed AB 1430, regulatory section 1783 is now in effect.
AB 141 (Knox), as amended August 16, would require
the Board to conduct a study of the incidence of medication
errors in pharmacies in California, and report its findings to
the legislature by December 1, 2004. [S. Appr]
AB 1496 (Olberg), as amended September 10, is no
longer relevant to the Board of Pharmacy. Prior versions of

the bill would have added section 4052.5 to the Business and
Professions Code to establish a new "home medical equipment services provider" licensure category under the Board
to replace the "medical device retailer" category, and expanded the definition of those who must be licensed as home
medical equipment services providers.
AB 660 (Cardenas), as amended April 28, is also a Y2K
bill authorizing pharmacists to refill prescriptions between
November 1, 1999 and February 29, 2000 under certain circumstances (see above). [S. B&P]
SB 404 (Alpert), as amended in March 1999, would authorize a pharmacist to initiate emergency contraception drug
therapy in accordance with written guidelines or protocols
previously established and approved for his/her practice by a
practitioner authorized to prescribe drugs. [S. B&P]

RECENT MEETINGS
At its May 20 meeting in San Diego, the Board elected
pharmacist Richard Mazzoni as its president, public member
Robert Elnser as vice-president, and public member Caleb
Zia as treasure.
At its May and July meetings, the Board discussed its ongoing difficulty in retaining experienced and qualified inspectors, pharmacists who are employed by the Board to investigate consumer and other complaints made to the Board about
licensees. At the May meeting, Executive Officer Patty Harris
reported that eight of the Board's 19 inspector positions were
vacant; by the July meeting, 10 of the 19 inspector positions
were vacant. The high attrition rate in Board inspector positions has been a serious problem since 1994, and is due in large
part to the low salary paid to Board inspectors. According to
Harris, the gap between Board inspector salaries and private
sector pharmacist positions is about $20,000; there is even a
substantial gap between the salary of Board inspectors and similar positions at other state agencies, which makes it very difficult for the Board to recruit and retain inspectors. Unfortunately for the Board, a provision in early versions of SB 1308
(Committee on Business and Professions) (Chapter 655, Statutes of 1999) requiring the salary of the Board's pharmacist
inspectors to be within 5% parity of pharmacists employed by
the University of California [16:2 CRLR 52] was deleted on
August 30 due to opposition by the Davis administration's
Department of Personnel Administration (DPA). However,
according to a Board memorandum distributed on October 12,
DPA has agreed to provide Board inspectors with a 10% augmentation in addition to the 4% increase for state employees.
Hopefully, this increase will stem the tide of vacancies and
permit the Board to shore up its staff of inspectors.

FUTURE MEETINGS
"
"
"
"

January 25-27,2000 in Riverside.
April 12-13, 2000 in Sacramento.
July 25-26,2000 in San Diego.
October 18-19,2000 in San Francisco.
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